Key facts
- Tune Therapeutics’s last known valuation is $340.0M (Jan 2025).
- It has raised $222.4M; the latest was Later Stage VC ($182.4M) in Jan 2025.
- Notable investors include New Enterprise Associates, Emerson Collective, Duke Capital Partners, Hatteras Venture Partners, Mission BioCapital — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Tune Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tune Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tune Therapeutics
Developer of an epigenetic programming platform designed to create new pathways for the treatment of disease. The company's platform helps to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases by tapping into the epigenome to program biology without altering the deoxyribonucleic acid sequence, enabling patients with treatments for pervasive diseases.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2020
- Employees
- 75
- Website
- tunetx.com/
- Ownership
- Privately Held (backing)
Tune Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tune Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tune Therapeutics in its N-PORT filings yet. We sweep new filings monthly.